Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RenovaCare, Inc. (RCAR)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
9375 East Shea Blvd 85260
Scottsdale, AZ, US
Scottsdale, AZ, US
CEO
Harmel Singh Rayat
Website
renovacareinc.com
IPO
1996-05-30
ISIN US75988J1060
Description
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.6K
Beta
-96.73
Float Shares
22.46M
Free Float %
25.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +9,900.00% | +9,900.00% | +0.00% | +0.00% | +0.00% | +0.00% | -98.00% | -100.00% | -100.00% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.03
+29,624.7%
DCF (Levered)
0.03
+32,168.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-76.98
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+53.6% ★ Q3'22: +163.4% (vs Q3'21)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'22: +209.6% (vs Q3'21)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q3'22: +0.0% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q3'22: -0.50× (vs Q3'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.03M
OE per share TTM
-0.03
Owner's Yield
-23,194.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,799.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sidhu, Jeet S. | 4.50M | 6.64% | 4.50M | — | 4.50M | — | IN | Canada | 2016-01-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
10.0K
Cash buys
—
Cash sales
—
Net activity
-10,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-04-01 | Trisler Patsy | Officer | — | D | Stock Option | 10,000 | 1.05 | 10.5K | 0 | — | ↗ |
| 2016-03-16 | SIERCHIO JOSEPH | Director | A-Award | A | Stock Option | 50,000 | 1.91 | 95.5K | 90,000 | — | ↗ |
| 2016-03-16 | Rosen Rhonda Beth | Officer | A-Award | A | Stock Option | 20,000 | 1.91 | 38.2K | 35,000 | — | ↗ |
| 2016-03-16 | Kirkland Kenneth | Director | A-Award | A | Stock Option | 50,000 | 1.91 | 95.5K | 90,000 | — | ↗ |
| 2016-02-02 | RAYAT HARMEL S | 10% Owner | P-Purchase | A | Common stock, par value $0.00001 | 2,173,913 | 0.46 | 1,000.0K | 44,550,713 | — | ↗ |
| 2015-12-31 | RAYAT HARMEL S | 10% Owner | J-Other | A | Common Stock, par value $0.00001 | 3,800,000 | 0.00 | — | 42,376,800 | — | ↗ |
| 2015-12-01 | Bold Thomas | Officer | — | D | Stock Option | 10,000 | 0.75 | 7.5K | 0 | — | ↗ |
| 2015-06-05 | Rosen Rhonda Beth | Officer | P-Purchase | A | Common Stock | 5,000 | 1.00 | 5.0K | 5,000 | — | ↗ |
| 2015-06-05 | Bold Thomas | Officer | P-Purchase | A | Series D Stock Purchase Warrant | 5,000 | 1.10 | 5.5K | 15,000 | — | ↗ |
| 2015-03-16 | Bold Thomas | Officer | A-Award | A | Stock Option | 60,000 | 1.91 | 114.6K | 105,000 | — | ↗ |
| 2014-08-14 | SIERCHIO JOSEPH | Director | A-Award | A | Stock Option | 20,000 | 0.80 | 16.0K | 40,000 | — | ↗ |
| 2014-08-14 | Rosen Rhonda Beth | Officer | A-Award | A | Stock options | 10,000 | 0.80 | 8.0K | 5,000 | — | ↗ |
| 2014-08-14 | Kirkland Kenneth | Director | A-Award | A | Stock Option | 20,000 | 0.80 | 16.0K | 40,000 | — | ↗ |
| 2013-11-29 | RAYAT HARMEL S | 10% Owner | P-Purchase | A | Common Stock, par value $0.00001 | 3,500,000 | 0.43 | 1.51M | 42,564,800 | — | ↗ |
| 2013-08-01 | SIERCHIO JOSEPH | Director | — | D | Stock Option | 20,000 | 0.65 | 13.0K | 0 | — | ↗ |
| 2013-08-01 | Kirkland Kenneth | Director | — | D | Stock Option | 20,000 | 0.65 | 13.0K | 0 | — | ↗ |
| 2013-07-12 | RAYAT HARMEL S | 10% Owner | P-Purchase | A | COMMON STOCK | 2,800,000 | 0.00 | 560.00 | 32,064,800 | — | ↗ |
| 2013-06-20 | Rosen Rhonda Beth | Director / Officer | — | D | Incentive Stock Option | 350,000 | 0.00 | — | 0 | — | ↗ |
| 2012-07-03 | Kalen Capital Corp | 10% Owner | P-Purchase | A | Common Shares | 3,500,000 | 0.01 | 35.0K | 29,264,800 | — | ↗ |
| 2012-07-03 | JENKINS DAVID E | Director | S-Sale | D | Common Shares | 3,500,000 | 0.01 | 35.0K | 0 | — | ↗ |
| 2011-12-23 | 1420525 ALBERTA LTD. | 10% Owner | A-Award | A | Common | 500,000 | 0.01 | 4.0K | 25,764,800 | — | ↗ |
| 2011-02-21 | 1420525 ALBERTA LTD. | 10% Owner | D-Return | D | Common | 50,000 | 0.01 | 500.00 | 25,264,800 | — | ↗ |
| 2010-10-22 | JENKINS DAVID E | Director | P-Purchase | A | Common Shares | 3,500,000 | 0.01 | 35.0K | 3,500,000 | — | ↗ |
| 2010-10-22 | Cacace Antonino G | Director / Officer | P-Purchase | A | Common Shares | 500,000 | 0.01 | 5.0K | 500,000 | — | ↗ |
| 2010-10-22 | 1420525 ALBERTA LTD. | 10% Owner | D-Return | D | Common | 7,325,000 | 0.01 | 73.3K | 25,314,800 | — | ↗ |
| 2010-10-21 | JENKINS DAVID E | Director | — | D | Common Shares | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-10-21 | Cacace Antonino G | Director / Officer | — | D | Common Shares | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-09-12 | Sidhu Jeet | Director | — | D | Stock Options | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2008-09-12 | Hudson Christian F | Director | — | D | Stock Options | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2008-09-12 | Fabio Frank J | Officer | — | D | Stock Options | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2008-09-12 | COOPER DEREK | Officer | — | D | Stock Options | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2008-09-08 | RAYAT HARMEL S | Director / Officer | D-Return | D | COMMON | 3,000,000 | 0.75 | 2.25M | 39,889,800 | — | ↗ |
| 2007-12-31 | RAYAT HARMEL S | Director / Officer / 10% Owner | D-Return | D | COMMON | 40,000,000 | 0.00 | — | 46,639,800 | — | ↗ |
| 2005-02-16 | RAYAT HARMEL S | Director / Officer / 10% Owner | S-Sale | D | Common | 1,000,000 | 1.50 | 1.50M | 86,639,800 | — | ↗ |
| 2004-12-29 | RAYAT HARMEL S | Director / 10% Owner | S-Sale | D | Common | 1,000,000 | 1.50 | 1.50M | 87,639,800 | — | ↗ |
| 2003-12-31 | WONG STANLEY | Officer | — | D | Common Stock | 0 | 0.00 | — | 440 | — | ↗ |
| 2003-12-31 | DUMOULIN TERRI | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
87.35M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2009 | Derek Cooper President, CEO, Chief Financial Officer and Director | — | — | — | — | — | — | 44.5K | 0.00% | ↗ |
| 2 | 2008 | Derek Cooper President, CEO, Chief Financial Officer and Director | — | — | — | 4.8K | — | — | 4.8K | 100.00% | ↗ |
| 3 | 2007 | Tim Luu Secretary, Treasurer Chief Technology Officer and Director | — | — | — | 3.0K | — | — | 3.0K | 100.00% | ↗ |
| 4 | 2007 | Tim Luu Secretary, Treasurer Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 5 | 2007 | Harmel S. Rayat President, CEO, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 6 | 2006 | Harmel S. Rayat President, CEO, Chief Financial Officer and Director | — | — | — | 4.5K | — | — | 4.5K | 100.00% | ↗ |
| 7 | 2006 | Tim Luu Secretary, Treasurer Chief Technology Officer and Director | — | — | — | 3.3K | — | — | 3.3K | 100.00% | ↗ |
| 8 | 2006 | Tim Luu Secretary, Treasurer Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 9 | 2006 | Harmel S. Rayat President, CEO, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 10 | 2005 | Harmel S. Rayat President, CEO, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 11 | 2005 | Tim Luu Secretary, Treasurer Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Justin Frere | Treasurer | 208.1K | male |
| Harmel S. Rayat | President, Chief Executive Officer, Chief Financial Officer & Interim Secretary | — | male |
| Jo Ellen Schweinle | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RCAR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
